According to the Complaint, Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.

This action stems from Defendants’ dissemination of a Proxy Statement filed with the United States Securities and Exchange Commission on November 21, 2019. The Complaint alleges that the Proxy Statement omits material information, which renders the Proxy Statement false and misleading.

This case was voluntarily dismissed on June 3, 2020.